PMY 302 Study Guide - Final Guide: Anterior Pituitary, Bone Age, Short Stature

• School: University at Buffalo
• Department: Pharmacology and Toxicology
• Course: PMY 302
• Professor: stewart Clark

Document Summary

Somatostatin (sst) inhibits gh release: gh stimulates igf-1 (insulin-like growth factor-1) secretion, predominantly from the liver. Both gh and igf-1 mediate growth promotion and anabolic effects: related therapies. Use: supplement growth in short stature conditions, especially children. Use: inhibitors of gh action, growth excess either somatostatin analogs/ gh receptor blockers. Acromegaly (excess gh in adult: idiopathic short stature. Bone growth is a principal diagnostic evaluation: idiopathic short stature. A clinical description rather than a disease. Children whose stature is 2 or more below the mean for average. And for those no endocrine, metabolic or other diagnosis can be made: turner syndrome (xo) Short stature and the lack of normal sexual development at puberty. Therapy: gh and estrogen replacement at 12 or younger: biochemical evaluation of gh deficiency. Affected children present with severe growth failure, delayed bone age and beryl pw serum igf-1 concentrations.